Annual Financials for ADC Therapeutics S.A.
Fiscal year is January-December. All values USD millions. |
2018 | 2019 | 2020 | 2021 | 2022 |
5-year trend |
Sales/Revenue
|
1.14M | 2.34M | - | 33.92M | 209.91M | |
Sales Growth |
- | 105.26% | - | - | 518.89% | |
Cost of Goods Sold (COGS) incl. D&A |
- | - | 1.97M | 3.97M | 6.83M | |
COGS excluding D&A |
- | - | - | 1.34M | 4.5M | |
Depreciation & Amortization Expense |
513,000 | 1.65M | 1.97M | 2.63M | 2.33M | |
Depreciation |
488,000 | 1.62M | 1.93M | 2.5M | 2.21M | |
Amortization of Intangibles |
25,000 | 30,000 | 47,000 | 129,000 | 118,000 | |
COGS Growth |
- | - | - | 101.47% | 71.96% | |
Gross Income |
- | - | (1.97M) | 29.94M | 203.08M | |
Gross Income Growth |
- | - | - | 1,618.46% | 578.19% | |
Gross Profit Margin |
- | - | - | - | 96.75% | NA |
|
2018 | 2019 | 2020 | 2021 | 2022 |
5-year trend |
SG&A Expense |
126.34M | 118.44M | 216.49M | 291.3M | 326.12M | |
Research & Development |
117.74M | 104.62M | 139.71M | 155.53M | 185.5M | |
Other SG&A |
8.6M | 13.81M | 76.78M | 135.77M | 141.06M | |
SGA Growth |
- | -6.26% | 82.79% | 34.55% | 11.95% | |
Other Operating Expense |
- | - | - | - | - | |
Unusual Expense |
227,000 | - | 47.2M | (34.89M) | 2.47M | |
EBIT after Unusual Expense |
(125.94M) | - | (265.66M) | (226.46M) | (125.51M) | |
Non Operating Income/Expense |
213,000 | (255,000) | (576,000) | 50,000 | (110,000) | |
Non-Operating Interest Income |
2.86M | 2.25M | 832,000 | 66,000 | 17.97M | |
Equity in Affiliates (Pretax) |
- | - | - | - | - | |
Interest Expense |
- | 156,000 | 4.93M | 18.49M | 36.92M | |
Interest Expense Growth |
- | - | 3,057.69% | 275.31% | 99.72% | |
Gross Interest Expense |
- | 156,000 | 4.93M | 18.49M | 36.92M | |
Interest Capitalized |
- | - | - | - | - | |
Pretax Income |
(122.87M) | (115.9M) | (270.33M) | (244.83M) | (144.58M) | |
Pretax Income Growth |
- | 5.67% | -133.24% | 9.43% | 40.95% | |
Pretax Margin |
- | - | - | - | -68.88% | NA |
Income Tax |
224,000 | 582,000 | 327,000 | (21.48M) | 1.14M | |
Income Tax - Current Domestic |
224,000 | 582,000 | 327,000 | 4.57M | 1.85M | |
Income Tax - Current Foreign |
- | - | - | - | - | |
Income Tax - Deferred Domestic |
- | - | - | (26.05M) | (708,000) | |
Income Tax - Deferred Foreign |
- | - | - | - | - | |
Income Tax Credits |
- | - | - | - | - | |
Equity in Affiliates |
- | - | 24.37M | (6.67M) | (10.08M) | |
Other After Tax Income (Expense) |
- | - | - | - | - | |
Consolidated Net Income |
(123.1M) | (116.48M) | (246.29M) | (230.03M) | (155.8M) | |
Minority Interest Expense |
- | - | - | - | - | |
Net Income |
(123.1M) | (116.48M) | (246.29M) | (230.03M) | (155.8M) | |
Net Income Growth |
- | 5.37% | -111.44% | 6.60% | 32.27% | |
Net Margin Growth |
- | - | - | - | -74.22% | NA |
Extraordinaries & Discontinued Operations |
- | - | - | - | - | |
Extra Items & Gain/Loss Sale Of Assets |
- | - | - | - | - | |
Cumulative Effect - Accounting Chg |
- | - | - | - | - | |
Discontinued Operations |
- | - | - | - | - | |
Net Income After Extraordinaries |
(123.1M) | (116.48M) | (246.29M) | (230.03M) | (155.8M) | |
Preferred Dividends |
- | - | - | - | - | |
Net Income Available to Common |
(123.1M) | (116.48M) | (246.29M) | (230.03M) | (155.8M) | |
EPS (Basic) |
(33,019.00) | (1.74) | (3.77) | (3.00) | (1.99) | |
EPS (Basic) Growth |
- | 99.99% | -116.16% | 20.40% | 33.49% | |
Basic Shares Outstanding |
3,728 | 66.87M | 65.41M | 76.75M | 78.15M | |
EPS (Diluted) |
(33,019.00) | (1.74) | (3.77) | (3.00) | (1.99) | |
EPS (Diluted) Growth |
- | 99.99% | -116.16% | 20.40% | 33.49% | |
Diluted Shares Outstanding |
3,728 | 66.87M | 65.41M | 76.75M | 78.15M | |
EBITDA |
(125.2M) | (116.1M) | (216.49M) | (258.72M) | (120.72M) | |
EBITDA Growth |
- | 7.27% | -86.47% | -19.51% | 53.34% | |
EBITDA Margin |
- | - | - | - | -57.51% | NA |